Meet the Holmusk team in the poster area and visit all 6 posters, including 5 posters co-presented by Boehringer Ingelheim and Holmusk at the 36th European College of Neuropsychopharmacology Congress, October 7 - 10, in Barcelona, Spain:
Download the PDF of our list of posters here.
Title: Psychometric evaluation of the PHQ-9 and the full and brief QIDS-C in a real-world population with major depressive disorder
Authors: Emily O.C. Palmer (Holmusk), Sheryl Ker (Holmusk), Miguel E. Rentería (QIMR Berghofer Medical Research Institute), and John A. Rush (Duke University School of Medicine)
Poster number: P.0830
Date: October 9, 2023
Time: 12:35 - 14:00
Location: Poster area at the Barcelona congress venue, virtual and in-person
Title: Clinical characteristics of people with borderline personality disorder at 12 months prior to first diagnosis and at diagnosis
Authors: Carissa White (Boehringer Ingelheim Pharmaceuticals), Suzanne St.Rose (Boehringer Ingelheim International GmbH), Jennifer Dwyer (Boehringer Ingelheim Pharmaceuticals), Emily O.C. Palmer (Holmusk), Joannas Yeow (Holmusk), Mayowa Oyesanya (Holmusk), Kira Griffiths (Holmusk), Benjamin Chee (Holmusk), Rashmi Patel (Institute of Psychiatry, Psychology, & Neuroscience, King’s College London)
Poster number: P.0844
Date: October 9, 2023
Time: 12:35 - 14:00
Location: Poster area at the Barcelona congress venue, virtual and in-person
Title: Examining differences in clinical and demographic characteristics of patients with post-traumatic stress disorder across adults and paediatric subgroups
Authors: Staci Abramsky (Boehringer Ingelheim Pharmaceuticals), Suzanne St.Rose (Boehringer Ingelheim International GmbH), Yi Wen Heng (Holmusk), L. Alexander Vance (Holmusk), Ling Zhang (Boehringer Ingelheim Pharmaceuticals), Kelly M.Y. Chan (Holmusk), Joshua G. Wong (Holmusk), Sherwin Kuah (Holmusk), Li Tong Low (Holmusk), Irina Adamczyk (Boehringer Ingelheim International GmbH)
Poster number: P.1250
Date: October 10, 2023
Time: 12:30 - 14:00
Location: Poster area at the Barcelona congress venue, virtual and in-person
Title: Examining real-world evidence of clinical outcomes, healthcare resource utilisation and treatment patterns of patients with post-traumatic stress disorder
Authors: Staci Abramsky (Boehringer Ingelheim Pharmaceuticals), Suzanne St.Rose (Boehringer Ingelheim International GmbH), L. Alexander Vance (Holmusk), Ling Zhang (Boehringer Ingelheim Pharmaceuticals), Kelly M.Y. Chan (Holmusk), Joshua G. Wong (Holmusk), Sherwin Kuah (Holmusk), Li Tong Low (Holmusk), Irina Adamczyk (Boehringer Ingelheim International GmbH)
Poster number: P.1251
Date: October 10, 2023
Time: 12:30-14:00
Location: Poster area at the Barcelona congress venue, virtual and in-person
Title: Treatment trajectory in people with borderline personality disorder from diagnosis to 12 months post-diagnosis
Authors: Carissa White (Boehringer Ingelheim Pharmaceuticals), Suzanne St.Rose (Boehringer Ingelheim International GmbH), Jennifer Dwyer (Boehringer Ingelheim Pharmaceuticals), Emily O.C. Palmer (Holmusk), Joannas Yeow (Holmusk), Mayowa Oyesanya (Holmusk), Kira Griffiths (Holmusk), Benjamin Chee (Holmusk), Rashmi Patel (Institute of Psychiatry, Psychology, & Neuroscience, King’s College London)
Poster number: P.1337
Date: October 10, 2023
Time: 12:30-14:00
Location: Poster area at the Barcelona congress venue, virtual and in-person
Title: Treatment trajectory in people with major depressive disorder from diagnosis to 12 months post-diagnosis
Authors: Suzanne St.Rose (Boehringer Ingelheim International GmbH), Carissa White (Boehringer Ingelheim Pharmaceuticals), Leonie Williams (Boehringer Ingelheim Pharmaceuticals), Emily O.C. Palmer (Holmusk), Sigurd D. Suessmuth (Boehringer Ingelheim), Joannas Yeow (Holmusk)
Poster number: P.1340
Date: October 10, 2023
Time: 12:30 - 14:00
Location: Poster area at the Barcelona congress venue, virtual and in-person
Holmusk is committed to conducting rigorous behavioral and mental health research leveraging our proprietary NeuroBlu Database. NeuroBlu is a powerful analytics platform designed to explore the richest source of longitudinal behavioral health real-world data, containing both structured and unstructured patient-level clinical data sourced from de-identified electronic health records. Our collaboration with Boehringer Ingelheim represents a significant step forward in our joint mission to improve the lives of individuals affected by mental health disorders. By combining the expertise in pharmaceutical research and development with cutting-edge real-world evidence analytics, we have harnessed the power of data-driven insights to drive innovation in behavioral health.
Interested in learning more? Reach out to discuss how NeuroBlu can enhance your studies, drive better evidence, and improve patient outcomes in behavioral and mental health. Contact us to schedule a demo.
